Patents by Inventor Ben Whalley

Ben Whalley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY
    Publication number: 20210100755
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Application
    Filed: September 4, 2020
    Publication date: April 8, 2021
    Inventors: Ben WHALLEY, Claire WILLIAMS, Gary STEPHENS, Takashi FUTAMURA
  • Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
    Patent number: 10799467
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: October 13, 2020
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co. Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
  • USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY
    Publication number: 20150320698
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Application
    Filed: April 14, 2015
    Publication date: November 12, 2015
    Inventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
  • Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
    Patent number: 9125859
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: September 8, 2015
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
  • Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
    Patent number: 9066920
    Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: June 30, 2015
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Ben Whalley, Gary Stephens, Claire Williams, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
  • USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY
    Publication number: 20140155456
    Abstract: The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.
    Type: Application
    Filed: January 3, 2012
    Publication date: June 5, 2014
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens
  • USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY
    Publication number: 20130296398
    Abstract: The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.
    Type: Application
    Filed: January 3, 2012
    Publication date: November 7, 2013
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens
  • USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY
    Publication number: 20120165402
    Abstract: This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
    Type: Application
    Filed: June 29, 2010
    Publication date: June 28, 2012
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Ben Whalley, Gary Stephens, Claire Willaims, Geoffrey Guy, Stephen Wright, Tetsuro Kikuchi
  • USE OF THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY
    Publication number: 20120004251
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Application
    Filed: March 30, 2011
    Publication date: January 5, 2012
    Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura